About Us

In this Section

2014 News Archive

December 9, 2014

Budapest, Hungary, and Zug, Switzerland (Dec 9, 2014) ImmunoGenes AG announced the publication of a paper in Nature Neuroscience that highlights the advantages of using the company's genetically-modified animals to generate antibodies against a difficult target. The paper describes a novel way to visualize proteins with high sensitivity and nanoscale localization precision in the brain using a highly-specific antibody to the cannabinoid receptor type 1 (CB1) that the companys FcRn-overexpressing rabbit produced. The research, in collaboration with the lab of Prof Istvn Katona working at the Institute of Experimental Medicine, Hungarian Academy of Sciences in Budapest, resulted in the article entitled "Cell type-specific STORM superresolution imaging reveals nanoscale organization of cannabinoid signaling at hippocampal GABAergic synapses" that was published online in Nature Neuroscience on December 8, 2014.

"Transgenic rabbits expressing elevated levels of the neonatal Fc receptor (FcRn) provide a novel tool for producing large amounts of antibodies with superior sensitivity and specificity," said Dr. Katona, a well-known molecular neuroscientist. "Compared with wild-type rabbits, FcRn-transgenic rabbits generated new and unique antibodies that were able to visualize drastically reduced levels of CB1 cannabinoid receptors after chronic treatment with delta-9-THC, the psychoactive compound in marijuana. The findings have strong relevance to human health, and the new antibody will offer the possibility of further development for therapeutically active monoclonal antibodies in common disorders like metabolic syndrome."

"The results of this study show the benefits of our exciting IMG-AbS patented technology to have a significant impact on life science research," said Imre Kacskovics, Chief Executive Officer of ImmunoGenes. "The ability of our genetically-modified animals to overcome the limitations in production of highly-specific antibodies against weakly-immunogenic targets, like the GPCR cannabinoid receptor type 1, is very promising and opens a new field for our business. There is a great need to produce antibodies against similarly challenging targets, like other GPCRs and ion channels, and we believe that our IMG-AbS technology combined with our knowledge and experience to produce such important antibodies will further facilitate great biological and medical discoveries."

June 5, 2014

Zug, Switzerland, and Budapest, Hungary (June 5, 2014) ImmunoGenes AG announced that the company has been selected to host a panel at the 2014 BIO International Convention in San Diego entitled "The Use of Transgenic Animals to Improve Antibody Production for Novel Therapies”.

Imre Kacskovics, Scientific Founder and co-CEO of ImmunoGenes, will host the panel. Joining him on the panel will be Peter Brams, Senior Director at Bristol-Myers Squibb, Allan Bradley, Chief Scientific Officer of Kymab, and Istvan Katona, Neurobiologist at the Hungarian Academy of Sciences. The panel will be held on Thursday, June 26, from 2:15pm-3:30pm, and more details are available at: http://mybio.org/event/member/103980.

Previously ImmunoGenes has shown that the company’s genetically-engineered mice and rabbits that overexpress the neonatal Fc receptor for IgG (FcRn) are able to generate more diverse antigen-specific antibodies and mount a stronger immune response against weakly immunogenic targets compared with wild-type mice. As a result, the company’s animals are of value for researchers seeking to develop antibodies against challenging immunogenic targets or who would benefit from the capability of these animals to express a more diverse immune response against epitopes of an antigen, which is typically not part of the standard response pattern.

“We are very excited to be hosting a panel at presenting at the 2014 BIO International Convention, the world’s largest biotechnology gathering” said Dr. Kacskovics. “The fact that BIO selected ImmunoGenes to host on panel on ways that genetically modified animals can help lead to important advances in the development of critical drugs and diagnostics underscores the unique advantages offered by our FcRn-overexpressing mice and rabbits.”

Lee Schalop, co-CEO of ImmunoGenes, added: “ImmunoGenes has recently signed agreements with both academic institutions and large pharmaceutical companies providing these organizations with the ability of using the company’s animals for the development of antibodies against targets that do not generate antibodies in wild-type animals. This presents a major advantage for researchers seeking to develop novel therapeutic or diagnostic antibodies. Presenting our technology at the 2014 BIO International Convention will allow more organizations to benefit from the company’s unique technology.”

Parties interested in meeting with Imre Kacskovics, or other members of the ImmunoGenes team should contact Lee Schalop at lee.schalop@immunogenes.com.

March 19, 2014

Zug, Switzerland, and Budapest, Hungary (March 19, 2014) – ImmunoGenes AG announced today that the company will present a poster describing its technology at the Antibody Biology & Engineering: Understanding Antibody Structure, Function, Diversity, and Pathology to Improve Disease Treatment, a Gordon Research Conference, March 23-28, 2014, at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.

Imre Kacskovics, CEO and scientific co-founder of ImmunoGenes, will present the poster entitled “Expanded antigen-specific T helper cell pool accompanied with augmented germinal center formation and IgG diversity in bovine FcRn transgenic mice upon immunization” describing how the company’s genetically engineered animals that overexpress the neonatal Fc receptor for IgG (FcRn) generate diverse antigen-specific antibodies and are thus able to mount a stronger immune response against weakly immunogenic targets aided by FcRn's role in antigen presentation. Dr. Kacskovics will be available to answer questions regarding the technology during his poster presentation at conference. In addition, parties interested in meeting with Dr. Kacskovics on an individual basis should contact him imre.kacskovics(at)immunogenes.com